Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results

-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enrollment in...
May 08, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronavirus...
March 17, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

--Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonstrating positive effect on all key liver...
March 09, 2020 16:30 ET | Source: NGM Biopharmaceuticals, Inc.

Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company

SOUTH SAN FRANCISCO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients,...
February 25, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients,...
February 24, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo

--Clinically meaningful response rates of 38% of patients treated with aldafermin having liver fibrosis improvement of ≥1 stage and 24% of patients achieving resolution of NASH at 24 weeks-- --22%...
February 23, 2020 16:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, February 24, 2020 at 8:30 a.m. ET...
February 11, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)

--Study to evaluate potential of GDF15/GFRAL pathway inhibition to block tumor-associated weight loss and tumor growth-- --CACS, an uncontrolled wasting syndrome, is a common co-morbidity of cancer...
December 05, 2019 17:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics...
November 14, 2019 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at the Stifel 2019 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics...